PAR-24-099 - NIAID SBIR Phase II Clinical Trial Implementation Cooperative Agreement (U44 Clinical Trial Required) is used for the submission of applications to the following Notices of Special Interest (NOSIs)
On This Page: 4
Active NOSIs
Title | Notice Number | Organization | Release Date |
Expiration Date |
Activity Code(s) |
---|---|---|---|---|---|
Notice of Special Interest (NOSI): Advancing Biomedical Research in Pulmonary Non-Tuberculous Mycobacterial (NTM) Infections | NOT-AI-23-050 | NIAID | Jun 27, 2023 | Jul 17, 2026 | R21, R41/R42, R43/R44, R01, U44 |
Notice of Special Interest (NOSI): Promoting Research and Development of Vaccines Against Enteric Viruses | NOT-AI-23-048 | NIAID | Jun 15, 2023 | Jul 17, 2026 | R01, R43/R44, U44, R41/R42, R21 |
Notice of Special Interest (NOSI): Advancing Research Needed to Develop a Coccidioidomycosis (Valley fever) Vaccine | NOT-AI-23-031 | NIAID | Feb 23, 2023 | Jan 15, 2026 | R01, R41/R42, R43/R44, R21, U44 |
Expired NOSIs
Title | Notice Number | Organization | Release Date |
Expiration Date |
Activity Code(s) |
---|---|---|---|---|---|
Notice of Special Interest (NOSI): Accelerating Progress in Celiac Disease Research | NOT-AI-22-004 | NIAID NIAMS NCCIH NCI | Nov 23, 2021 | Jan 8, 2025 | R03, R21, U01, U44, R01, R34, P01, R61/R33 |